Whilst the potential efficacy of HDAC inhibitors such as Panobinostat has been relatively neglected in MYCN-driven Grp4 and SHH MB, data from studies of MYCN-driven NB may provide evidence for HDAC inhibitors having similar effects on MYCN activity to those seen in MYC-driven cell lines. The gene discussed is MYC; the disease is neuroblastoma.